Sharemaestro Newsreel

Check-Cap (NASDAQ: MBAI) targets Q3 2026 close for MBody AI merger

Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Waters (WAT) Is Up 5.1% After Raising 2026 Revenue Guidance Amid Integration Progress – What’s Changed

Can BillionToOne (BLLN) Justify Its Price On Earnings And Reaffirmed 2026 Guidance?

BillionToOne (BLLN) Stock Price Cracks As Rich Expectations Meet Reality

How IDEXX’s Raised 2026 Earnings Outlook Will Impact IDEXX Laboratories (IDXX) Investors

IDEXX Labs Is Maintained at Neutral by UBS

UBS has maintained its "Neutral" rating on IDEXX Labs (IDXX) stock. This indicates that the analyst believes the stock will perform in line with the market. No specific financial data or price targets were provided in this brief announcement.

Guardant Health (GH) Stock May Be Below Fair Value After Raised Guidance

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : BAIRD RAISES TARGET PRICE TO $291 FROM $255

Baird has increased its target price for Charles River Laboratories International, Inc. (CRL.N) from $255 to $291. This update reflects a positive outlook from the analytical firm regarding the company's financial prospects. The news was reported by Reuters.

BillionToOne Stock Stumbles After Hitting Fresh High

Bank of America Corp DE Cuts Stake in Labcorp Holdings Inc. $LH

Bank of America Corp DE reduced its stake in Labcorp Holdings Inc. by 1.6% in the first quarter of 2026, selling 11,524 shares but still holding 724,811 shares valued at $193.4 million. Despite this reduction, institutional investors collectively own 95.94% of Labcorp, and analysts …

GeneDx (WGS) Stock Climbs On Strong Margins As Reimbursement Lags

GeneDx Holdings Corp. (WGS) saw its stock climb 4.8% after reporting strong Q2 2026 results, with exome and genome revenue reaching US$100.3 million and a gross margin of around 70%. The company achieved adjusted profitability ahead of schedule, demonstrating its core engine's efficiency. However, …

Guardant Health (NASDAQ: GH) insider files to sell 1,700 shares

Manuel Hidalgo Medina, an insider at Guardant Health (NASDAQ: GH), has filed a Form 144 indicating an intent to sell up to 1,700 shares of common stock through Charles Schwab & Co., Inc. The proposed sale, valued at $279,202.00, is supported by upcoming restricted …

Charles River Laboratories International, Inc. reports results for the quarter ended June 30 - Earnings Summary

Charles River Laboratories International, Inc. has released its earnings summary for the quarter that concluded on June 30. The article, sourced from Reuters, provides a brief announcement of these results. Readers can access the full report and more news on TradingView.

BlackRock, Inc. Adds to Sotera Health Co (SHC) Stake -- Shares S

BillionToOne, Inc. (BLLN) CEO reports 45,000-share sale, option exercise

BillionToOne, Inc.'s Chairman and CEO, Atay Oguzhan, reported the exercise of stock options for 32,500 shares at $2.80 each and the sale of 45,000 Class A Common Stock shares. These transactions were executed on August 3, 2026, under a Rule 10b5-1 trading plan adopted …

Natera executive (NASDAQ: NTRA) logs 3,410-share sale under Rule 10b5-1 plans

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ: NTRA), sold a total of 3,410 shares of common stock on August 3, 2026. These sales, conducted under Rule 10b5-1 plans, included shares sold to cover tax withholding obligations on RSU vesting and additional …

Natera (NTRA) co-founder sells 109 shares to cover RSU-related taxes

Jonathan Sheena, co-founder and director of Natera, Inc. (NTRA), sold 109 shares of common stock on August 3, 2026, at a price of $267.9893 per share. This sale was conducted to fulfill tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) …

Natera (NASDAQ: NTRA) CEO stock sales cover RSU taxes, 10b5-1 plan

Natera, Inc. CEO and President Steven Leonard Chapman sold a total of 3,076 shares of common stock on August 3, 2026. A portion of these sales, specifically 1,182 shares, was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units …

Natera (NTRA) CFO logs 795-share stock sales for taxes and Rule 10b5-1

Natera's Chief Financial Officer, Michael Burkes Brophy, reported two sales of common stock totaling 795 shares. These sales, executed on August 3 and August 4, 2026, were made to cover tax obligations related to RSU vesting and through a Rule 10b5-1 trading plan. After …

Revvity Inc. Lifts Guidance After Strong Earnings

Revvity Inc. reported strong Q2 earnings, exceeding revenue and EPS guidance, leading to raised full-year targets. The Diagnostics segment and high-content screening orders were key growth drivers, while software revenue experienced volatility. The company also demonstrated strong cash flow, deleveraging progress, and an accelerated …

Waters Corp Earnings Call Highlights Growth And Upside

Waters Corp (WAT) recently held its Q2 earnings call, revealing strong organic growth, accelerating performance in acquired businesses, and successful cost-cutting measures. Despite headwinds from foreign exchange rates, China exposure, and integration costs, the company exceeded guidance, raised its full-year adjusted EPS and revenue …

Icon PLC (ICLR) Stock Up 4.2% and Still Undervalued -- GF Score: 93/100

Icon PLC (ICLR) saw its shares rise by 4.2% to $163.51, yet it is considered undervalued with a GF Value™ estimate of $211.85, offering a 22.8% margin of safety. The company holds a strong GF Score™ of 93/100, driven by high profitability and growth …

XWELL appoints Gerard Reid to board of directors

XWELL, Inc. (NASDAQ:XWEL) has announced the immediate appointment of Gerard Reid to its Board of Directors. Concurrently, Ezra Ernst has resigned from the board to focus solely on his role as President and Chief Executive Officer. Reid brings 25 years of experience in energy, …

Results: Veracyte, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Veracyte, Inc. exceeded analyst expectations for its quarterly results, with revenues hitting US$150m and statutory EPS at US$0.31, 19% above forecasts. Following these positive results, analysts have slightly increased their earnings per share outlook for 2026, though the consensus revenue estimates remain largely unchanged. …

Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates

Qiagen (QGEN) exceeded Q2 earnings and revenue estimates, reporting $0.62 per share against a $0.60 consensus and revenues of $535.04 million, surpassing the $527.91 million estimate. Despite the beat, the company's shares have underperformed the S&P 500 year-to-date, and its Zacks Rank of #4 …

Twist Bioscience Nets ~$327 Million From $96-Per-Share Underwritten Stock Offering

Twist Bioscience has successfully completed an underwritten stock offering, selling 3,125,000 shares of common stock at $96.00 per share, with the underwriters fully exercising their option for an additional 468,750 shares. This offering is expected to generate approximately $327.1 million in net proceeds after …

BLLN (NASDAQ: BLLN) holders plan sale of 15,539 Class A shares

Affiliated shareholders of BillionToOne, Inc. (BLLN) have filed a Form 144 to sell up to 15,539 Class A shares through a stock option exercise, with a proposed sale date of August 5, 2026. The aggregate market value of these shares is $2,331,352.23, and the …

Planned 46,963-share sale reported by CDNA insider (CDNA)

A Form 144 notice for CareDx, Inc. (CDNA) indicates a proposed sale of up to 46,963 shares of common stock, valued at $2,178,945.34 as of August 5, 2026, through Morgan Stanley Smith Barney LLC. These shares originate from restricted stock grants and a stock …

Arrowstreet Capital Limited Partnership Purchases New Shares in Quest Diagnostics Incorporated $DGX

Arrowstreet Capital Limited Partnership initiated a new position in Quest Diagnostics (NYSE:DGX) by acquiring 11,468 shares valued at approximately $2.25 million. This move comes as institutional investors now own 88.06% of the company, and several analysts have raised price targets following Quest Diagnostics' strong …

Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates

Biodesix, Inc. (BDSX) reported a Q2 loss of $0.71 per share, which beat the Zacks Consensus Estimate of a $0.86 loss, marking a 17.44% surprise. The company's revenues for the quarter reached $26.86 million, exceeding estimates by 2.92% and showing growth from $20.02 million …

Guardant Health (GH) insider files to sell 1,803,685 shares valued at $134M

An insider at Guardant Health (GH), Meghan V. Joyce, has filed a notice to sell up to 1,803,685 shares of common stock, valued at approximately $134 million, through Charles Schwab & Co., Inc. The proposed sale date is August 5, 2026, on NASDAQ. The …

Twist Bioscience (TWST) Jumps As Guidance, Offering Reset The Trade

Twist Bioscience (TWST) saw its stock jump over 16% after reporting strong Q3 revenue, exceeding consensus, and raising its Q4 and FY26 revenue guidance. The company also announced an upsized $300M stock offering to fund R&D and manufacturing expansion, which, despite dilution, is seen …

LABCORP HOLDINGS 2026: Revenue $3.73B, EPS $3.64— 10-Q Summary

Labcorp Holdings (LH) reported strong second-quarter 2026 results, with revenue reaching $3.73 billion and diluted EPS of $3.64. The company experienced a 5.8% year-over-year revenue growth due to increased test utilization, price/mix gains, and margin expansion. Labcorp also highlighted increased capital spending and strategic …

Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market

Shares of Thermo Fisher Scientific Inc. (TMO) rose 2.32% on Wednesday, closing at $577.83, and outperforming the broader market. The increase broke a three-day losing streak for the stock. This occurred during a mixed trading session where the Dow Jones Industrial Average gained 0.49% …

Twist Bioscience (NASDAQ: TWST) COO sells 2,888 shares for tax withholding

Patrick John Finn, President and COO of Twist Bioscience (NASDAQ: TWST), sold 2,888 shares of common stock on August 3, 2026, at an average price of $85.3212 per share. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations related to …